With the FDA showing once again that it is willing to ignore the recommendations of its own...

|By:, SA News Editor

With the FDA showing once again that it is willing to ignore the recommendations of its own panels, investors in MELA Sciences ([[MELA]] +3.7%) will have some nervous days ahead of a final decision on the MelaFind, as the FDA clearly had concerns with this application.